Thermo Fisher Scientific Inc. $TMO Shares Sold by Marietta Investment Partners LLC

Marietta Investment Partners LLC cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 18.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,361 shares of the medical research company’s stock after selling 1,220 shares during the period. Marietta Investment Partners LLC’s holdings in Thermo Fisher Scientific were worth $2,635,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the stock. DGS Capital Management LLC lifted its stake in Thermo Fisher Scientific by 13.7% during the first quarter. DGS Capital Management LLC now owns 749 shares of the medical research company’s stock worth $368,000 after purchasing an additional 90 shares in the last quarter. Ascentis Independent Advisors grew its stake in shares of Thermo Fisher Scientific by 101.9% in the first quarter. Ascentis Independent Advisors now owns 5,319 shares of the medical research company’s stock valued at $2,614,000 after buying an additional 2,685 shares in the last quarter. Stephens Inc. AR boosted its holdings in Thermo Fisher Scientific by 8.6% during the 1st quarter. Stephens Inc. AR now owns 23,680 shares of the medical research company’s stock valued at $11,639,000 after acquiring an additional 1,869 shares during the period. Steigerwald Gordon & Koch Inc. grew its position in Thermo Fisher Scientific by 17.6% in the 1st quarter. Steigerwald Gordon & Koch Inc. now owns 414 shares of the medical research company’s stock valued at $204,000 after acquiring an additional 62 shares in the last quarter. Finally, GM Advisory Group LLC increased its stake in Thermo Fisher Scientific by 12.3% during the first quarter. GM Advisory Group LLC now owns 3,208 shares of the medical research company’s stock worth $1,577,000 after purchasing an additional 351 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently weighed in on TMO shares. DZ Bank started coverage on shares of Thermo Fisher Scientific in a report on Friday, March 27th. They issued a “buy” rating and a $610.00 price objective for the company. Piper Sandler assumed coverage on shares of Thermo Fisher Scientific in a research report on Thursday, June 11th. They issued a “neutral” rating and a $510.00 price target for the company. Sanford C. Bernstein started coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a “market perform” rating and a $520.00 price target for the company. Stifel Nicolaus reduced their price objective on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a research note on Friday, April 24th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $620.00 target price on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $605.09.

Thermo Fisher Scientific Trading Down 0.2%

NYSE TMO opened at $522.38 on Monday. Thermo Fisher Scientific Inc. has a 52 week low of $403.36 and a 52 week high of $643.99. The firm has a 50 day moving average of $473.17 and a two-hundred day moving average of $517.74. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $194.13 billion, a PE ratio of 28.72, a price-to-earnings-growth ratio of 2.32 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. The business had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s revenue was up 6.2% on a year-over-year basis. During the same period last year, the business earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be issued a $0.47 dividend. The ex-dividend date is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.